SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY ARTICLE M impact

Blackstone Life Sciences to Provide $750M for OLN324 Phase 3 Program

Funds managed by Blackstone Life Sciences will provide $750 million to Johnson & Johnson following the expected closing of its acquisition of Ollin. The agreement is subject to the acquisition closing and customary conditions, including regulatory approvals.

BX

Funds managed by Blackstone Life Sciences will provide $750M to Johnson & Johnson for OLN324's Phase 3 program, following the expected closing of Johnson & Johnson's acquisition of Ollin. The agreement is subject to the acquisition closing and customary conditions, including regulatory approvals.Ma…

Related stories